Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-Arm, Multicenter Trial of BGB-A317 as a Second-Line Treatment for Patients with Previously Treated, PD-L1-Positive, Locally Advanced or Metastatic Urothelial Cancer (UC)

Trial Profile

A Phase II, Single-Arm, Multicenter Trial of BGB-A317 as a Second-Line Treatment for Patients with Previously Treated, PD-L1-Positive, Locally Advanced or Metastatic Urothelial Cancer (UC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 07 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in the BeiGene media release.
    • 28 Feb 2018 According to a BeiGene media release, enrollment completion is expected in 2018.
    • 07 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top